Answer
In clinical trials, 26.1% of kidney transplant recipients receiving basiliximab with dual or triple immunosuppressive therapy experienced serious infections, compared with 24.8% receiving placebo with these regimens.
Sources for this answer
- Simulect 10 mg powder for solution for injection or infusionNovartis Pharmaceuticals UK Ltd · emc · SmPC §4.8 Undesirable effects · Version 1Document updated
Sources checked